p73 beta-expressing recombinant adenovirus: a potential anticancer agent

Area of Science:

• Molecular Biology
• Cancer Research
• Gene Therapy

Background:

• Tumor suppressor p53 gene therapy is limited in some cases.
• p73, a p53 homologue, is crucial for cancer cell chemosensitivity.
• Replication-deficient adenovirus expressing p73 beta (Ad-p73) has been developed.

Purpose of the Study:

• To evaluate the therapeutic potential of Ad-p73 against various cancer cell lines.
• To investigate the mechanism of Ad-p73-induced cytotoxicity.
• To assess Ad-p73's ability to enhance chemosensitivity and its safety in normal cells.

Main Methods:

• Infection of 12 cancer cell lines and normal cells with Ad-p73.
• Quantification of p73 beta levels and activation of target gene p21(WAF1/CIP1).
• Assessment of cell cycle arrest, apoptosis, and chemosensitivity to adriamycin.

Main Results:

• Ad-p73 efficiently infected all tested cancer cell lines, increasing p73 beta levels and activating p21(WAF1/CIP1).
• Ad-p73 induced potent cytotoxicity through cell cycle arrest and apoptosis in cancer cells.
• Ad-p73 significantly enhanced cancer cell chemosensitivity to adriamycin and showed greater efficacy than Ad-p53 in mutant p53 cells.
• Ad-p73 did not induce apoptosis in normal human lung fibroblasts (HEL 299) or keratinocytes (HaCaT).

Conclusions:

• Ad-p73 is a potent cytotoxic agent specifically targeting cancer cells.
• Ad-p73 demonstrates potential as a standalone cancer gene therapy or in combination with chemotherapy.
• Ad-p73 offers a promising alternative for gene therapy, especially when p53-based strategies are ineffective.